<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>8428097</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">34503441</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmc">8428097</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">1318</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1186/s10194-021-01318-3</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical data for all participants</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical data for all participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Clinical details</th><th align="left">MOH + CM<sup>a</sup> patients</th><th align="left">EM<sup>b</sup> patients</th><th align="left">Healthy controls</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Age, years</td><td align="left">46.6 ± 10.3</td><td align="left">38.0 ± 14.4</td><td align="left">40.8 ± 9.7</td><td align="left">0.078</td></tr><tr><td align="left">Sex</td><td align="left">3M<sup>c</sup>, 14F<sup>d</sup></td><td align="left">4 M, 14 F</td><td align="left">11 M, 19 F</td><td align="left">0.298</td></tr><tr><td align="left">Headache history, years</td><td align="left">22.8 ± 8.9</td><td align="left">10.8 ± 6.9</td><td align="left"> N/A<sup>e</sup></td><td align="left">&lt; 0.001</td></tr><tr><td align="left">Medication-overuse duration, years</td><td align="left">7.3 ± 6.4</td><td align="left"> N/A</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left" colspan="5">Headache location</td></tr><tr><td align="left">Right; Left; Bilateral</td><td align="left">2 (11.8 %); 2 (11.8 %); 13 (76.5 %)</td><td align="left">2 (11.1 %); 7 (38.9 %); 9 (50 %)</td><td align="left">N/A; N/A; N/A</td><td align="left">N/A; N/A; N/A</td></tr><tr><td align="left">VAS<sup>f</sup></td><td align="left">8.4 ± 1.4</td><td align="left">8.0 ± 1.4</td><td align="left"> N/A</td><td align="left">0.465</td></tr><tr><td align="left">PHQ9</td><td align="left">8.7 ± 6.7</td><td align="left">2.4 ± 4.8</td><td align="left">2.5 ± 2.2</td><td align="left">&lt; 0.05<sup>h</sup></td></tr><tr><td align="left">GAD-7<sup>i</sup></td><td align="left">2.9 ± 3.9</td><td align="left">1.6 ± 3.6</td><td align="left">2.6 ± 2.1</td><td align="left">0.729</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> MOH + CM, medication-overuse headache + chronic migraine; <sup>b</sup> EM, episodic migraine; <sup>c</sup> M, male; <sup>d</sup> F, female; <sup>e</sup> NA, not applicable; <sup>f</sup> VAS, visual analog scale; <sup>g</sup> PHQ-9, Patient Health Questionnaire 9 Depression Scale; <sup>h</sup> Post-hoc analysis using LSD resulted significant difference between MOH + CM and EM with <italic>p</italic> value of 0.018, MOH + CM with HC with <italic>p</italic> value of 0.002. Meanwhile there was no significant difference between EM and HC with <italic>p</italic> value of 0.978; <sup>i</sup> GAD-7, Generalized Anxiety Disorder Assessment 7-item Scale. Data are mean ± standard deviation</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical data for all participants</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left">Clinical details</th><th align="left">MOH + CMa patients</th><th align="left">EMb patients</th><th align="left">Healthy controls</th><th align="left">p value</th></tr></thead><tbody><tr><td align="left">Age, years</td><td align="left">46.6 ± 10.3</td><td align="left">38.0 ± 14.4</td><td align="left">40.8 ± 9.7</td><td align="left">0.078</td></tr><tr><td align="left">Sex</td><td align="left">3Mc, 14Fd</td><td align="left">4 M, 14 F</td><td align="left">11 M, 19 F</td><td align="left">0.298</td></tr><tr><td align="left">Headache history, years</td><td align="left">22.8 ± 8.9</td><td align="left">10.8 ± 6.9</td><td align="left"> N/Ae</td><td align="left">&lt; 0.001</td></tr><tr><td align="left">Medication-overuse duration, years</td><td align="left">7.3 ± 6.4</td><td align="left"> N/A</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left" colspan="5">Headache location</td></tr><tr><td align="left">Right; Left; Bilateral</td><td align="left">2 (11.8 %); 2 (11.8 %); 13 (76.5 %)</td><td align="left">2 (11.1 %); 7 (38.9 %); 9 (50 %)</td><td align="left">N/A; N/A; N/A</td><td align="left">N/A; N/A; N/A</td></tr><tr><td align="left">VASf</td><td align="left">8.4 ± 1.4</td><td align="left">8.0 ± 1.4</td><td align="left"> N/A</td><td align="left">0.465</td></tr><tr><td align="left">PHQ9</td><td align="left">8.7 ± 6.7</td><td align="left">2.4 ± 4.8</td><td align="left">2.5 ± 2.2</td><td align="left">&lt; 0.05h</td></tr><tr><td align="left">GAD-7i</td><td align="left">2.9 ± 3.9</td><td align="left">1.6 ± 3.6</td><td align="left">2.6 ± 2.1</td><td align="left">0.729</td></tr></tbody></table></div>a MOH + CM, medication-overuse headache + chronic migraine; b EM, episodic migraine; c M, male; d F, female; e NA, not applicable; f VAS, visual analog scale; g PHQ-9, Patient Health Questionnaire 9 Depression Scale; h Post-hoc analysis using LSD resulted significant difference between MOH + CM and EM with p value of 0.018, MOH + CM with HC with p value of 0.002. Meanwhile there was no significant difference between EM and HC with p value of 0.978; i GAD-7, Generalized Anxiety Disorder Assessment 7-item Scale. Data are mean ± standard deviation</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>Altered resting-state functional connectivity of the habenula and the SNa amongst MOH + CMb, EMc and HCd, and between MOH + CM subgroups with or without depression</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab2"><label>Table 2</label><caption><p>Altered resting-state functional connectivity of the habenula and the SN<sup>a</sup> amongst MOH + CM<sup>b</sup>, EM<sup>c</sup> and HC<sup>d</sup>, and between MOH + CM subgroups with or without depression</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Brain region</th><th align="left" rowspan="2">Number of voxels</th><th align="left" rowspan="2">Cluster size, mm<sup>3</sup></th><th align="left" colspan="3">MNI coordinates, mm</th><th align="left" rowspan="2">F score (max)</th><th align="left" rowspan="2"><italic>p</italic> value</th></tr><tr><th align="left">x</th><th align="left">y</th><th align="left">z</th></tr></thead><tbody><tr><td align="left" colspan="8">MOH + CM VS HC</td></tr><tr><td align="left">  R<sup>e</sup> habenula</td><td char="." align="char">7</td><td char="." align="char">56</td><td align="left">4</td><td align="left">-25</td><td char="." align="char">2</td><td align="left">3.38</td><td align="left">&lt; 0.001</td></tr><tr><td align="left">  L<sup>f</sup> habenula</td><td char="." align="char">7</td><td char="." align="char">56</td><td align="left">-3</td><td align="left">-25</td><td char="." align="char">2</td><td align="left">3.09</td><td align="left">0.002</td></tr><tr><td align="left" colspan="8">MOH + CM VS EM</td></tr><tr><td align="left">  R habenula</td><td char="." align="char">7</td><td char="." align="char">56</td><td align="left">4</td><td align="left">-23</td><td char="." align="char">2</td><td align="left">2.73</td><td align="left">0.006</td></tr><tr><td align="left">   L habenula</td><td char="." align="char">7</td><td char="." align="char">56</td><td align="left">-3</td><td align="left">-23</td><td char="." align="char">2</td><td align="left">3.03</td><td align="left">0.002</td></tr><tr><td align="left" colspan="8">EM VS HC</td></tr><tr><td align="left">  R habenula</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left">3</td><td align="left">-25</td><td char="." align="char">2</td><td align="left">1.76</td><td align="left">0.079</td></tr><tr><td align="left">   L habenula</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left">4</td><td align="left">-24</td><td char="." align="char">2</td><td align="left">1.51</td><td align="left">0.132</td></tr><tr><td align="left" colspan="8">MOH + CM <sup>depression</sup> VS MOH + CM <sup>without depression</sup></td></tr><tr><td align="left">  R habenula</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left">5</td><td align="left">-24</td><td char="." align="char">2</td><td align="left">0.85*</td><td align="left">0.475</td></tr><tr><td align="left">  L habenula</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left">4</td><td align="left">-24</td><td char="." align="char">2</td><td align="left">1.99*</td><td align="left">0.077</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> SN, salience network; <sup>b</sup> MOH + CM, medication-overuse headache + chronic migraine; <sup>c</sup> EM, episodic migraine; <sup>d</sup> HC, healthy controls; <sup>e</sup> R, right; <sup>f</sup> L, left</p><p>*T score from two-sample t test</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Altered resting-state functional connectivity of the habenula and the SNa amongst MOH + CMb, EMc and HCd, and between MOH + CM subgroups with or without depression</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Brain region</th><th align="left" rowspan="2">Number of voxels</th><th align="left" rowspan="2">Cluster size, mm3</th><th align="left" colspan="3">MNI coordinates, mm</th><th align="left" rowspan="2">F score (max)</th><th align="left" rowspan="2">p value</th></tr><tr><th align="left">x</th><th align="left">y</th><th align="left">z</th></tr></thead><tbody><tr><td align="left" colspan="8">MOH + CM VS HC</td></tr><tr><td align="left">  Re habenula</td><td char="." align="char">7</td><td char="." align="char">56</td><td align="left">4</td><td align="left">-25</td><td char="." align="char">2</td><td align="left">3.38</td><td align="left">&lt; 0.001</td></tr><tr><td align="left">  Lf habenula</td><td char="." align="char">7</td><td char="." align="char">56</td><td align="left">-3</td><td align="left">-25</td><td char="." align="char">2</td><td align="left">3.09</td><td align="left">0.002</td></tr><tr><td align="left" colspan="8">MOH + CM VS EM</td></tr><tr><td align="left">  R habenula</td><td char="." align="char">7</td><td char="." align="char">56</td><td align="left">4</td><td align="left">-23</td><td char="." align="char">2</td><td align="left">2.73</td><td align="left">0.006</td></tr><tr><td align="left">   L habenula</td><td char="." align="char">7</td><td char="." align="char">56</td><td align="left">-3</td><td align="left">-23</td><td char="." align="char">2</td><td align="left">3.03</td><td align="left">0.002</td></tr><tr><td align="left" colspan="8">EM VS HC</td></tr><tr><td align="left">  R habenula</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left">3</td><td align="left">-25</td><td char="." align="char">2</td><td align="left">1.76</td><td align="left">0.079</td></tr><tr><td align="left">   L habenula</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left">4</td><td align="left">-24</td><td char="." align="char">2</td><td align="left">1.51</td><td align="left">0.132</td></tr><tr><td align="left" colspan="8">MOH + CM depression VS MOH + CM without depression</td></tr><tr><td align="left">  R habenula</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left">5</td><td align="left">-24</td><td char="." align="char">2</td><td align="left">0.85*</td><td align="left">0.475</td></tr><tr><td align="left">  L habenula</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left">4</td><td align="left">-24</td><td char="." align="char">2</td><td align="left">1.99*</td><td align="left">0.077</td></tr></tbody></table></div>a SN, salience network; b MOH + CM, medication-overuse headache + chronic migraine; c EM, episodic migraine; d HC, healthy controls; e R, right; f L, left*T score from two-sample t test</transformed-table></extracted-table><extracted-table><table-id>Tab3</table-id><table-label>Table 3</table-label><table-caption>Correlation analysis between functional connectivity of habenula-SN and clinical variables of MOH + CMa subjects</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab3"><label>Table 3</label><caption><p>Correlation analysis between functional connectivity of habenula-SN and clinical variables of MOH + CM<sup>a</sup> subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Clinical variables</th><th align="left">r</th><th align="left"><italic>p</italic> value</th><th align="left">95 % CI of r</th></tr></thead><tbody><tr><td align="left">Headache history</td><td>0.103</td><td>0.703</td><td>-0.204–0.557</td></tr><tr><td align="left">Medication overuse duration</td><td>0.512</td><td>0.043</td><td>0.116–0.790</td></tr><tr><td align="left">Attack frequency</td><td>0.299</td><td>0.260</td><td>-0.451–0.702</td></tr><tr><td align="left">VAS<sup>b</sup></td><td>0.205</td><td>0.446</td><td>-0.300–0.714</td></tr><tr><td align="left">PHQ-9<sup>c</sup></td><td>0.482</td><td>0.158</td><td>-0.333–0.882</td></tr><tr><td align="left">GAD-7<sup>d</sup></td><td>0.206</td><td>0.568</td><td>-0.488–0.659</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> MOH + CM medication-overuse headache + chronic migraine; <sup>b</sup> VAS visual analog scale; <sup>c</sup> PHQ-9 Patient Health Questionnaire 9 Depression Scale; <sup>d</sup> GAD-7 Generalized Anxiety Disorder Assessment 7-item Scale</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Correlation analysis between functional connectivity of habenula-SN and clinical variables of MOH + CMa subjects</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left">Clinical variables</th><th align="left">r</th><th align="left">p value</th><th align="left">95 % CI of r</th></tr></thead><tbody><tr><td align="left">Headache history</td><td>0.103</td><td>0.703</td><td>-0.204–0.557</td></tr><tr><td align="left">Medication overuse duration</td><td>0.512</td><td>0.043</td><td>0.116–0.790</td></tr><tr><td align="left">Attack frequency</td><td>0.299</td><td>0.260</td><td>-0.451–0.702</td></tr><tr><td align="left">VASb</td><td>0.205</td><td>0.446</td><td>-0.300–0.714</td></tr><tr><td align="left">PHQ-9c</td><td>0.482</td><td>0.158</td><td>-0.333–0.882</td></tr><tr><td align="left">GAD-7d</td><td>0.206</td><td>0.568</td><td>-0.488–0.659</td></tr></tbody></table></div>a MOH + CM medication-overuse headache + chronic migraine; b VAS visual analog scale; c PHQ-9 Patient Health Questionnaire 9 Depression Scale; d GAD-7 Generalized Anxiety Disorder Assessment 7-item Scale</transformed-table></extracted-table></extracted-tables-set>